
June 2, 2021 Briefing

Bioengineering for COVID-19


Bruce J. Tromberg, Ph.D. Director, National Institute of Biomedical Imaging & Bioengineering (NIBIB)





Bioengineering for COVID-19

NIBIB Strategy





1) Imaging and AI
2) Digital Health Platforms
3) Diagnostic Test Technologies



Medical Imaging and Data Resource Center (MIDRC)



Kris Kandarpa *Chair*



Guoying Liu Scientific Program Lead



Behrouz Shabestari NIBIB National Technology Center Program Director



Maryellen Giger (PI) AAPM, University of Chicago

National Institute of Biomedical Imaging and Bioengineering https://www.nibib.nih.gov/news-events/newsroom/nihharnesses-ai-covid-19-diagnosis-treatment-and-monitoring



Two-year, \$20M contract: Medical Imaging/Data Science

Thoracic imaging and clinical data repository for COVID 19

Develop, validate ML/AI for detection, diagnosis, Tx

60,000 curated COVID-19 chest radiographs and CTs+clinical data



Radiological Society of North America









MEDICAL IMAGING AND DATA RESOURCE CENTER.

Infrastructure


National Institute of

Biomedical Imaging and Bioengineering

NIF

• 5 Technology Development Projects

Data ingestion, data quality and harmonization




Operational

In parallel, AI/ML development

(12 Collaborative Research Projects)24 algorithms developed /under development.

Segmentation of lung and lung opacities



 Prediction of Covid-19 severity and length of hospital stay from multi-modal data (EHR and Imaging)

1 algorithm undergoing validation

 Comparing AI determination of Covid-19 severity from chest CT data to steroid use during hospitalization (data from Wuhan)




RADx: Unexpected Opportunity April 24, 2020: \$1.5B to NIH \$500 Million to NIBIB

April 29

NIH Office of the Director







ak Tara Schwetz

RADx Tech – \$500M

Highly competitive, rapid three-phase challenge to identify the best candidates for athome or point-of-care tests for COVID-19

RADx Advanced Technology Platforms (RADx-ATP) - \$230M

Rapid scale-up of advanced technologies to increase rapidity and enhance and validate throughput – create ultra-high throughput machines and facilities

1) Expand COVID-19 Testing Technologies: Number, Type and Access 2) Optimize Performance: Technologic and Operational; Match Community Needs



National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Jill Heemskerk. Bruce Tromberg

RADx Radical (RADx-Rad) – \$200M

National Institute of Biomedical Imaging and Bioengineering

Develop and advance novel, non-traditional approaches or new applications of existing approaches for testing

RADx Underserved Populations (RADx-UP) - \$500M

Interlinked community-based demonstration projects focused on implementation strategies to enable and enhance testing of COVID-19 in vulnerable populations

https://www.nih.gov/research-training/medical-research-initiatives/radx



\$307 M Partnership






Point-of-Care Technologies Research Network (POCTRN)


NIBIB National Network: NHLBI, NIAID, NCCIH, FIC, OBSSR, OAR, ODP

Established 2007, Expanded 2020: >900 RADx experts & contributors

(USG, Academia, Industry, NFP)




RADx Tech Innovation Funnel



National Institute of Biomedical Imaging and Bioengineering

RADx Impact thru April 2021



Major Milestones


- ~300 million capacity thru April 2021
- ~2 M tests and products/day April 2021
- 23 EUAs; 1st OTC EUA, 2 "at home"
- >100 companies supported

- Sequential use screening guidance An tests
- Pooling use guidance for POC PCR
- Pediatric use guidance for self swabbing


https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-dashboard



Nano applications to RADx-Tech



RADx-Tech Applications and Funded Proposals






Mesa BioTech





Visby Medical



Fluidigm

NIH



Luminostics




DHL RS Antigen SAR

Quidel QuickVue

Quidel Sophia







Genbody



ANP



Point of Care	& Home	
Visby		RTPCR
Mesa		RTPCR
MicroGem		RTPCR
Talis		ISO-PCR
Ubiquitome		RTPCR
Meridian		RTPCR
GenBody		An-LFA
Quidel Sophia		An-LFA
Quidel QuickView	K	An-LFA
Luminostics	Home Rx	An-LFA
ANP	& OTC	An-LFA
Ellume 📉		An-LFA
Xtrava Home C	ЭТС	An-LFA
Qorvo		An-BAW
Mologic		An-LFA
Maxim		An-LFA
Laboratory		
Flambeau		PCR-mobile-lab
MatMaCorp		RTPCR-mini-lab
Fluidigm		RTPCR
Broad Inst		RTPCR
Illumina		NGS
Helix		NGS/RTPCR
Gingko		NGS/RTPCR
Sonic Healthcare		RTPCR
PathGroup		RTPCR
PathogenDx		RTPCR
Aegis		RTPCR
Quanterix		SIMOA (An)
Minute Molecular		RTPCR
Lab Products		
Mammoth Biosci		CRISPR
Ceres Nanosciences		Beads/Conc
Oasis		Saliva Collect

Swabs

Yukon

National Institute of Biomedical Imaging and Bioengineering

https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-phase2-awards

Assess the **effectiveness** of **at**home testing 3 times a week in reducing community transmission over 4 weeks

> 2 million free home tests Greenville, NC; Chattanooga, TN

Outcome measures:

- SARS-CoV-2 prevalence and incidence
- % test positivity
- Cell phone mobility
- Wastewater surveillance

Optional app used for:

- Ordering tests (partnership with Amazon)
- Reminders and instructions
- Interpretation & guidance when positive
- Reporting results to the state (TN only)







https://www.nih.gov/news-events/news-releases/cdcnih-bring-covid-19-self-testing-residents-two-locales



RADx UP

SAY YES!


JOIN THE FREE AT-HOME TESTING CHALLENGE

Duke Clinical Research Institute **IDUNC** Clinical Research Institute

National Institutes of Health

urning Discovery Into Health





Summary

RADx and MIDRC: New process for acceleration and impact

- Leverage existing networks w/added capabilities for evaluation, validation, funding
- Connect with partners to meet regulatory, policy, and deployment goals

Nano: Tech, materials, manufacturing huge drivers of RADx

- ~15-20% of total RADx investment, # of applications, cumulative test capacity
- Tech de-risked, validated, accelerated to market

Diagnostic Technology future

- Leverage semi-conductor & telecom w/nano-tech and biomaterials
- Multiplexed tests with other pathogens, variants, diseases

